Another of the biopharma startups created as part of a collaboration between San Diego investment firm Avalon Ventures and GlaxoSmithKline has been acquired—but not by GSK.
Instead, the company, Calporta Therapeutics, is being absorbed by Merck (NYSE: MRK), which is interested in its preclinical work on potential treatments for lysosomal storage and neurodegenerative diseases, including Alzheimer’s and Parkinson’s.
Calporta, like the other companies launched from the Avalon-GSK (NYSE: GSK) deal, has been incubating at COI Pharmaceuticals, a shared space in La Jolla, CA, created by Avalon for its portfolio companies.
Debuting in COI (which stands for “community of innovation”)… Read more »
UNDERWRITERS AND PARTNERS
